Albireo Announces 2022 SPARK Grant Winners
03 nov. 2022 08h30 HE
|
Albireo Pharma, Inc.
— Eight projects selected for inaugural year of the program — Projects provide solutions to make a tangible difference in the lives of PFIC patients BOSTON, Nov. 03, 2022 (GLOBE...
Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia
02 nov. 2022 08h30 HE
|
Albireo Pharma, Inc.
– BOLD is the first, largest, and only global Phase 3 trial designed to meet regulatory agencies' requirements – On track to report topline data by the end of 2024, reinforcing Bylvay's expected...
Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022
01 nov. 2022 08h30 HE
|
Albireo Pharma, Inc.
– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS) – Oral late breaker provides evidence of disease modification in PFIC – Analysis of...
Albireo to Report Q3 2022 Financial Results on November 8, 2022
31 oct. 2022 08h30 HE
|
Albireo Pharma, Inc.
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a...
Albireo informa de datos positivos de primera línea del ensayo de fase 3 sobre Bylvay® (odevixibat) en el síndrome de Alagille
19 oct. 2022 02h00 HE
|
Albireo Pharma, Inc.
Mejoría estadísticamente muy significativa en el criterio de valoración principal «prurito» (p = 0,002)Reducciones significativas en el criterio de valoración secundario clave «niveles de ácidos...
Albireo annuncia i risultati cardine dello studio di Fase 3 di Bylvay® (odevixibat) nella Sindrome di Alagille
19 oct. 2022 02h00 HE
|
Albireo Pharma, Inc.
Miglioramento statisticamente molto significativo dell'endpoint primario del prurito (p=0,002)Significative riduzioni dell'endpoint chiave secondario dei livelli di acidi biliari nel siero...
Albireo meldet positive Topline-Daten aus Phase-3-Studie zu Bylvay® (Odevixibat) beim Alagille-Syndrom
19 oct. 2022 02h00 HE
|
Albireo Pharma, Inc.
Hochgradige statistisch signifikante Linderung von Juckreiz, dem primären Endpunkt (p=0,002)Signifikante Verringerung des Gallensäurespiegels im Serum, dem wichtigsten sekundären Endpunkt...
Albireo annonce des données clés positives à l’issue de la phase III sur Bylvay® (odevixibat) pour le traitement contre le syndrome d'Alagille
19 oct. 2022 02h00 HE
|
Albireo Pharma, Inc.
Amélioration statistiquement significative du critère d'évaluation primaire du prurit (p = 0,002).Réductions significatives du critère d'évaluation secondaire des niveaux d'acides biliaires sériques...
Albireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay® Treatment at NASPGHAN
13 oct. 2022 08h30 HE
|
Albireo Pharma, Inc.
– New data presented at the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition meeting (NASPGHAN) – Earlier treatment with Bylvay (odevixibat) provided greater efficacy...
Albireo to Participate in H.C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
12 oct. 2022 08h30 HE
|
Albireo Pharma, Inc.
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...